# [18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma

Source: https://onco.cc/trials/nct04252859/  
OnCo record `nct04252859` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of FES PET in Breast cancer, run by University of Utah, recorded as terminated on the registry.

## Summary

[18F]Fluoroestradiol-PET/CT Imaging of Invasive Lobular Carcinoma is a phase 2 interventional study registered as NCT04252859 by University of Utah, with 44 participants recorded, started 2020-12-11 and due to reach its primary completion in 2024-12-07. Interventions recorded: [18F]Fluoroestradiol (FES) PET/CT. Conditions recorded: Invasive Lobular Breast Carcinoma.

Linked to the technology FES PET because the registry's title names it ("18f fluoroestradiol pet") and Breast cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04252859
- Phase: 2
- Setting: [18F]Fluoroestradiol-Positron Emission Tomography (PET)/CT Imaging of Invasive Lobular Carcinoma
- Sponsor: University of Utah
- Enrolled: 44

## Sources

- ClinicalTrials.gov NCT04252859: https://clinicaltrials.gov/study/NCT04252859

## Connected records

- cancers: [Breast cancer (all types)](https://onco.cc/cancers/breast-cancer/)
- technologies: [FES PET (oestrogen receptor imaging)](https://onco.cc/technologies/fes-pet/)

---
JSON: https://onco.cc/api/v1/entities/nct04252859.json